Yumol Jenalyn L, Binda Sylvie, Nagulesapillai Varuni, Bhardwaj Renu, Ward Wendy E
Department of Kinesiology, Brock University, St. Catharines, ON, Canada.
Centre for Bone and Muscle Health, Brock University, 1812 Sir Isaac Brock Way, St. Catharines, ON, L2S3A1, Canada.
Arch Osteoporos. 2025 Jul 27;20(1):103. doi: 10.1007/s11657-025-01589-2.
Studies using rodent models have demonstrated the ability for probiotics to attenuate estrogen-related bone loss, but findings in humans are limited. Postmenopausal women consuming a novel combination of bacteria strains as a probiotic supplement demonstrated no changes in bone health outcomes.
This study determined if a probiotic supplement could attenuate the loss of femoral neck bone mineral density (BMD) and assessed its effect on fracture risk and markers of bone cell activity.
Seventy-two postmenopausal women (40-59 years) were randomized to a daily probiotic supplement or placebo for 48 weeks. Femoral neck BMD was assessed at weeks 0 and 48 using DXA along with fracture risk using the FRAX® assessment tool. Serum procollagen type 1 N-terminal propeptide (P1NP), bone-specific alkaline phosphatase (BALP), cross-linked C-telopeptide of type I collagen (CTx), and osteocalcin (OC) were analyzed at weeks 0, 12, 24, and 48.
There was no significant time by treatment interaction (p > 0.05) for femoral neck BMD or fracture risk. Independent of treatment, femoral neck BMD decreased (p = 0.034), while risk of hip (p = 0.003) and major osteoporotic fracture (p = 0.044) increased. There was no mean difference in bone marker levels between groups from baseline to endpoint. These findings align with the lack of difference in BMD and fracture risk at the end of study.
Probiotics did not alter BMD or fracture risk, as supported by bone cellular activity that was similar to the placebo group by the end of study.
使用啮齿动物模型的研究已证明益生菌有减轻雌激素相关骨质流失的能力，但在人类中的研究结果有限。绝经后女性服用一种新型菌株组合作为益生菌补充剂，其骨骼健康结果未出现变化。
本研究确定一种益生菌补充剂是否能减轻股骨颈骨矿物质密度（BMD）的流失，并评估其对骨折风险和骨细胞活性标志物的影响。
72名绝经后女性（40 - 59岁）被随机分为每日服用益生菌补充剂组或安慰剂组，为期48周。在第0周和第48周使用双能X线吸收法（DXA）评估股骨颈BMD，并使用FRAX®评估工具评估骨折风险。在第0、12、24和48周分析血清1型前胶原N端前肽（P1NP）、骨特异性碱性磷酸酶（BALP）、I型胶原交联C端肽（CTx）和骨钙素（OC）。
对于股骨颈BMD或骨折风险，治疗与时间之间无显著交互作用（p > 0.05）。与治疗无关，股骨颈BMD下降（p = 0.034），而髋部骨折风险（p = 0.003）和主要骨质疏松性骨折风险（p = 0.044）增加。从基线到终点，两组之间骨标志物水平无平均差异。这些结果与研究结束时BMD和骨折风险无差异一致。
益生菌未改变BMD或骨折风险，研究结束时骨细胞活性与安慰剂组相似，支持了这一结论。
